Knowledge Translation in Glomerulonephritis: Successes in Translational Research From the Bench to Bedside
Purpose of review: Glomerulonephritis refers to a rare group of diseases characterized by glomerular inflammation, which collectively are a common cause of kidney failure. Until recently, there was a lack of high-quality clinical trials to inform the care of patients with glomerulonephritides. We id...
Saved in:
| Published in: | Canadian Journal of Kidney Health and Disease Vol. 10; p. 20543581231191839 |
|---|---|
| Main Authors: | , , , , , |
| Format: | Book Review Journal Article |
| Language: | English |
| Published: |
Los Angeles, CA
SAGE Publications
01-01-2023
Sage Publications Ltd SAGE Publishing |
| Subjects: | |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Abstract | Purpose of review:
Glomerulonephritis refers to a rare group of diseases characterized by glomerular inflammation, which collectively are a common cause of kidney failure. Until recently, there was a lack of high-quality clinical trials to inform the care of patients with glomerulonephritides. We identified examples of successful translational research spanning from basic science to clinical applications, and highlight gaps in implementation science.
Sources of information:
The focus of our review was derived from discussions between health care professionals, researchers, and patient partners. We also performed literature searches pertaining to the treatment of glomerulonephritis in PubMed and Google Scholar.
Methods:
Examples of successful knowledge translation were generated through review of new evidence in the past 5 years and by iterative discussions by the authors. We then conducted a narrative review of several themes related to knowledge translation in glomerulonephritis. This was complemented by an interview with a patient partner to provide an example of a patient’s perspective living with glomerulonephritis.
Key findings:
We summarized selected recent advances in glomerulonephritis and its knowledge translation in the following domains: (1) identification of auto-antibodies in membranous nephropathy and minimal change disease; (2) clinical trials of novel targeted therapies for IgA nephropathy and lupus nephritis, which have led to approval of new treatments; (3) developments in research networks and clinical trials in glomerulonephritis; (4) recognition of the importance in developing standardized patient reported outcome measures in clinical trials; and (5) barriers in knowledge translation including access to medication.
Limitations:
A systematic search of the literature and formal assessment of quality of evidence were beyond the scope of this review. |
|---|---|
| AbstractList | Purpose of review: Glomerulonephritis refers to a rare group of diseases characterized by glomerular inflammation, which collectively are a common cause of kidney failure. Until recently, there was a lack of high-quality clinical trials to inform the care of patients with glomerulonephritides. We identified examples of successful translational research spanning from basic science to clinical applications, and highlight gaps in implementation science. Sources of information: The focus of our review was derived from discussions between health care professionals, researchers, and patient partners. We also performed literature searches pertaining to the treatment of glomerulonephritis in PubMed and Google Scholar. Methods: Examples of successful knowledge translation were generated through review of new evidence in the past 5 years and by iterative discussions by the authors. We then conducted a narrative review of several themes related to knowledge translation in glomerulonephritis. This was complemented by an interview with a patient partner to provide an example of a patient’s perspective living with glomerulonephritis. Key findings: We summarized selected recent advances in glomerulonephritis and its knowledge translation in the following domains: (1) identification of auto-antibodies in membranous nephropathy and minimal change disease; (2) clinical trials of novel targeted therapies for IgA nephropathy and lupus nephritis, which have led to approval of new treatments; (3) developments in research networks and clinical trials in glomerulonephritis; (4) recognition of the importance in developing standardized patient reported outcome measures in clinical trials; and (5) barriers in knowledge translation including access to medication. Limitations: A systematic search of the literature and formal assessment of quality of evidence were beyond the scope of this review. Glomerulonephritis refers to a rare group of diseases characterized by glomerular inflammation, which collectively are a common cause of kidney failure. Until recently, there was a lack of high-quality clinical trials to inform the care of patients with glomerulonephritides. We identified examples of successful translational research spanning from basic science to clinical applications, and highlight gaps in implementation science. The focus of our review was derived from discussions between health care professionals, researchers, and patient partners. We also performed literature searches pertaining to the treatment of glomerulonephritis in PubMed and Google Scholar. Examples of successful knowledge translation were generated through review of new evidence in the past 5 years and by iterative discussions by the authors. We then conducted a narrative review of several themes related to knowledge translation in glomerulonephritis. This was complemented by an interview with a patient partner to provide an example of a patient's perspective living with glomerulonephritis. We summarized selected recent advances in glomerulonephritis and its knowledge translation in the following domains: (1) identification of auto-antibodies in membranous nephropathy and minimal change disease; (2) clinical trials of novel targeted therapies for IgA nephropathy and lupus nephritis, which have led to approval of new treatments; (3) developments in research networks and clinical trials in glomerulonephritis; (4) recognition of the importance in developing standardized patient reported outcome measures in clinical trials; and (5) barriers in knowledge translation including access to medication. A systematic search of the literature and formal assessment of quality of evidence were beyond the scope of this review. Purpose of reviewGlomerulonephritis refers to a rare group of diseases characterized by glomerular inflammation, which collectively are a common cause of kidney failure. Until recently, there was a lack of high-quality clinical trials to inform the care of patients with glomerulonephritides. We identified examples of successful translational research spanning from basic science to clinical applications, and highlight gaps in implementation science. Sources of informationThe focus of our review was derived from discussions between health care professionals, researchers, and patient partners. We also performed literature searches pertaining to the treatment of glomerulonephritis in PubMed and Google Scholar. MethodsExamples of successful knowledge translation were generated through review of new evidence in the past 5 years and by iterative discussions by the authors. We then conducted a narrative review of several themes related to knowledge translation in glomerulonephritis. This was complemented by an interview with a patient partner to provide an example of a patient's perspective living with glomerulonephritis. Key findingsWe summarized selected recent advances in glomerulonephritis and its knowledge translation in the following domains: (1) identification of auto-antibodies in membranous nephropathy and minimal change disease; (2) clinical trials of novel targeted therapies for IgA nephropathy and lupus nephritis, which have led to approval of new treatments; (3) developments in research networks and clinical trials in glomerulonephritis; (4) recognition of the importance in developing standardized patient reported outcome measures in clinical trials; and (5) barriers in knowledge translation including access to medication. LimitationsA systematic search of the literature and formal assessment of quality of evidence were beyond the scope of this review. Purpose of review: Glomerulonephritis refers to a rare group of diseases characterized by glomerular inflammation, which collectively are a common cause of kidney failure. Until recently, there was a lack of high-quality clinical trials to inform the care of patients with glomerulonephritides. We identified examples of successful translational research spanning from basic science to clinical applications, and highlight gaps in implementation science. Sources of information: The focus of our review was derived from discussions between health care professionals, researchers, and patient partners. We also performed literature searches pertaining to the treatment of glomerulonephritis in PubMed and Google Scholar. Methods: Examples of successful knowledge translation were generated through review of new evidence in the past 5 years and by iterative discussions by the authors. We then conducted a narrative review of several themes related to knowledge translation in glomerulonephritis. This was complemented by an interview with a patient partner to provide an example of a patient’s perspective living with glomerulonephritis. Key findings: We summarized selected recent advances in glomerulonephritis and its knowledge translation in the following domains: (1) identification of auto-antibodies in membranous nephropathy and minimal change disease; (2) clinical trials of novel targeted therapies for IgA nephropathy and lupus nephritis, which have led to approval of new treatments; (3) developments in research networks and clinical trials in glomerulonephritis; (4) recognition of the importance in developing standardized patient reported outcome measures in clinical trials; and (5) barriers in knowledge translation including access to medication. Limitations: A systematic search of the literature and formal assessment of quality of evidence were beyond the scope of this review. |
| Author | Wang, Carol Farragher, Janine F. Macphee, Anne Al Batran, Rami Yau, Kevin Beaucage, Mary |
| AuthorAffiliation | 7 Provincial Patient and Family Advisory Council, Ontario Renal Network, Toronto, Ontario, Canada 5 Patient Governance Council, Indigenous Peoples’ Engagement and Research Council, Can-SOLVE CKD, Vancouver, BC, Canada 8 Department of Occupational Science & Occupational Therapy, Faculty of Medicine, University of Toronto, Toronto, ON, Canada 2 Division of Nephrology, Western University, London, ON, Canada 4 Kidney Research Scientist Core Education and National Training Patient Community Advisory Network, Montreal, QC, Canada 6 The Canadian Donation and Transplantation Research Program, Edmonton, AB, Canada 1 Division of Nephrology, University of Toronto, Toronto, ON, Canada 3 Faculte de Pharmacie, Universite de Montreal, Montreal, QC, Canada |
| AuthorAffiliation_xml | – name: 2 Division of Nephrology, Western University, London, ON, Canada – name: 6 The Canadian Donation and Transplantation Research Program, Edmonton, AB, Canada – name: 7 Provincial Patient and Family Advisory Council, Ontario Renal Network, Toronto, Ontario, Canada – name: 1 Division of Nephrology, University of Toronto, Toronto, ON, Canada – name: 8 Department of Occupational Science & Occupational Therapy, Faculty of Medicine, University of Toronto, Toronto, ON, Canada – name: 5 Patient Governance Council, Indigenous Peoples’ Engagement and Research Council, Can-SOLVE CKD, Vancouver, BC, Canada – name: 3 Faculte de Pharmacie, Universite de Montreal, Montreal, QC, Canada – name: 4 Kidney Research Scientist Core Education and National Training Patient Community Advisory Network, Montreal, QC, Canada |
| Author_xml | – sequence: 1 givenname: Kevin orcidid: 0000-0001-8653-6778 surname: Yau fullname: Yau, Kevin – sequence: 2 givenname: Carol orcidid: 0000-0003-0225-8307 surname: Wang fullname: Wang, Carol – sequence: 3 givenname: Rami surname: Al Batran fullname: Al Batran, Rami – sequence: 4 givenname: Anne surname: Macphee fullname: Macphee, Anne – sequence: 5 givenname: Mary surname: Beaucage fullname: Beaucage, Mary – sequence: 6 givenname: Janine F. surname: Farragher fullname: Farragher, Janine F. email: janine.farragher@utoronto.ca |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/37637870$$D View this record in MEDLINE/PubMed |
| BookMark | eNp1kk1v1DAQhiNUREvpD-CCInHhssWfscMFQdWWikpIUM6WY493vfLai52A-Pd12FK2IE6eGT_zzofmaXMQU4SmeY7RKcZCvCaIM8olJhTjHkvaP2qO5thiDh7s2YfNSSlrhBAmnIseP2kOqeiokAIdNeuPMf0IYJfQ3mQdS9CjT7H1sb0MaQN5CrXqdpX96Mub9stkDJQCZQb2eB3az1BAZ7NqL3LatOMK2vcQqzumatjiLTxrHjsdCpzcvcfN14vzm7MPi-tPl1dn764XhjEyLnqqjaXOaewMQYgYLGiHiBy4M501hPCBC2MZSIQMWKk5ttg65rioMzpHj5urna5Neq222W90_qmS9upXIOWl0nn0JoBCUg-kLpMSItjAOs15dbGRBPXUkVnr7U5rOw0bsAbimHV4IPrwJ_qVWqbvCiPGBSeoKry6U8jp2wRlVBtfDISgI6SpKCK5ZEiynlf05V_oOk25LrdSPUG4J7jvKoV3lMmplAzuvhuM1HwZ6p_LqDkv9se4z_h9BxU43QFFL-FP2f8r3gLJ7MJT |
| Cites_doi | 10.1038/ki.2014.143. 10.1016/j.ekir.2020.08.003. 10.5301/jn.5000218. 10.1200/EDBK_200383. 10.1056/NEJMoa2001180. 10.1038/ki.2010.156. 10.1016/j.kint.2021.04.027. 10.1016/S0140-6736(16)00272-5. 10.1681/ASN.2021060794. 10.1177/2054358119879451. 10.1002/art.42657 10.1053/j.ajkd.2021.01.024. 10.1016/S0140-6736(21)00578-X. 10.2215/CJN.04710420. 10.1016/j.kint.2022.10.019. 10.1016/S0140-6736(10)61354-2. 10.1080/13543784.2022.2160315. 10.1001/jama.2022.5368. 10.1186/s12882-021-02551-3. 10.1016/j.kint.2021.05.015. 10.1056/NEJMoa1415463. 10.1016/j.kint.2021.09.012. 10.1182/asheducation-2015.1.501. 10.1681/ASN.2020091254. 10.3181/00379727-100-24736. 10.3390/jcm10112493. 10.1136/annrheumdis-2021-220920. 10.1681/ASN.2015010091. 10.1681/ASN.2018080852. 10.1001/jamanetworkopen.2022.54054. 10.1053/j.ajkd.2019.10.017. 10.1172/JCI72270. 10.1186/s12913-020-05557-z. 10.1136/annrheumdis-2021-221478. 10.1093/ckj/sfab012. 10.1016/j.jacc.2003.12.043. 10.1038/ki.2012.428. 10.1007/s11255-018-2022-7. 10.1016/j.kint.2020.05.030. 10.1093/ndt/gfq665. 10.1681/ASN.2011050464. 10.1186/1471-2369-14-236. 10.1177/2054358118799690. 10.1016/j.ijnurstu.2017.06.008. 10.1097/MD.0000000000003099. 10.1016/j.kint.2022.09.017. 10.1016/j.kint.2021.05.021. 10.1177/20543581211004803. 10.1056/NEJMoa2023386. 10.1016/j.molimm.2019.07.017. 10.1136/annrheumdis-2022-eular.4162. 10.1056/NEJMoa0810457. 10.1016/j.kint.2019.09.014. 10.1186/s41687-021-00365-3. 10.1016/S0140-6736(03)14184-0. 10.1016/j.kint.2018.12.018. 10.1111/ajt.15267. 10.1038/s41591-022-02017-5. 10.1177/2054358118759551. 10.1177/2054358119877405. 10.1056/NEJMoa1409354. 10.2215/CJN.08600718. 10.1097/MNH.0000000000000881. 10.1097/MNH.0000000000000792. 10.1093/ndt/gfw235. 10.1001/jama.2017.9362. 10.1002/art.30613. 10.1177/20543581221089094. 10.1056/NEJMoa1803537. 10.1093/ckj/sfu104. 10.1016/j.ekir.2020.06.041. 10.1016/j.kint.2021.12.003. 10.2215/CJN.13101019. 10.1136/bmj.f167. 10.1093/ndt/gfaa264. 10.1053/j.ajkd.2019.06.009. 10.2215/CJN.05480421. 10.1681/ASN.2020081165. 10.1177/08968608221096560. 10.1016/s0272-6386(88)80022-2. |
| ContentType | Book Review Journal Article |
| Copyright | The Author(s) 2023 The Author(s) 2023. The Author(s) 2023. This work is licensed under the Creative Commons Attribution – Non-Commercial License https://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. The Author(s) 2023 2023 Canadian Society of Nephrology, unless otherwise noted. Manuscript content on this site is licensed under Creative Commons Licenses |
| Copyright_xml | – notice: The Author(s) 2023 – notice: The Author(s) 2023. – notice: The Author(s) 2023. This work is licensed under the Creative Commons Attribution – Non-Commercial License https://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: The Author(s) 2023 2023 Canadian Society of Nephrology, unless otherwise noted. Manuscript content on this site is licensed under Creative Commons Licenses |
| DBID | AFRWT NPM AAYXX CITATION 3V. 7X7 7XB 88C 8FI 8FJ 8FK 8FQ 8FV ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FYUFA GHDGH K9. M0S M0T PIMPY PQEST PQQKQ PQUKI Q9U 7X8 5PM DOA |
| DOI | 10.1177/20543581231191839 |
| DatabaseName | SAGE Open Access Journals PubMed CrossRef ProQuest Central (Corporate) ProQuest_Health & Medical Collection ProQuest Central (purchase pre-March 2016) Healthcare Administration Database (Alumni) Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Canadian Business & Current Affairs Database Canadian Business & Current Affairs Database (Alumni Edition) ProQuest Central (Alumni) ProQuest Central ProQuest Central Essentials ProQuest Central ProQuest One Community College ProQuest Central Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Health & Medical Complete (Alumni) Health & Medical Collection (Alumni Edition) ProQuest Healthcare Administration Database Publicly Available Content Database ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central Basic MEDLINE - Academic PubMed Central (Full Participant titles) Directory of Open Access Journals |
| DatabaseTitle | PubMed CrossRef Publicly Available Content Database ProQuest Central Basic ProQuest Central Essentials ProQuest One Academic Eastern Edition ProQuest Health & Medical Complete (Alumni) ProQuest Health Management ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) ProQuest Central CBCA Complete (Alumni Edition) ProQuest Health & Medical Complete Health Research Premium Collection ProQuest One Academic UKI Edition Health and Medicine Complete (Alumni Edition) ProQuest Central Korea ProQuest Health Management (Alumni Edition) CBCA Complete ProQuest One Academic ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | CrossRef PubMed MEDLINE - Academic Publicly Available Content Database |
| Database_xml | – sequence: 1 dbid: DOA name: Directory of Open Access Journals url: http://www.doaj.org/ sourceTypes: Open Website |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 2054-3581 |
| EndPage | 20543581231191839 |
| ExternalDocumentID | oai_doaj_org_article_08ab217732274b46a552171c82093f2f 10_1177_20543581231191839 37637870 10.1177_20543581231191839 |
| Genre | Journal Article Review |
| GroupedDBID | 0R~ 31X 3V. 54M 5VS 7X7 8FI 8FJ 8FQ AATBZ ABQXT ABUWG ABVFX ACARO ACGFS ACGZU ACRMQ ACROE ACSIQ ADBBV ADINQ ADOGD ADPDF ADRAZ ADUKV AEWDL AEWHI AFCOW AFGXO AFKRA AFKRG AFRWT AHBYD AHSBF AHYZX AIOMO AJUZI ALIPV ALMA_UNASSIGNED_HOLDINGS AMKLP AOIJS AQUVI ASPBG AUTPY AYAKG BAWUL BCNDV BDDNI BENPR BFQNJ BMC BPHCQ BSEHC BVXVI C24 C6C CCPQU DC. DIK DV7 DWQXO EBS EJD EMOBN FYUFA GROUPED_DOAJ GROUPED_SAGE_PREMIER_JOURNAL_COLLECTION HMCUK HYE J8X K.F KQ8 M0T M48 M~E O9- OK1 OVD OVEED PIMPY PQQKQ PROAC ROL RPM RSV SFC SFK SFT SGV SOJ SPP TEORI UKHRP H13 NPM PGMZT AAYXX CITATION 7XB 8FK AZQEC K9. PQEST PQUKI Q9U 7X8 5PM |
| ID | FETCH-LOGICAL-c442t-93acd3ffa1fc2002c1736028b5fc6dc225b57cd4e800ced8a51d1df4f57000ff3 |
| IEDL.DBID | RPM |
| ISSN | 2054-3581 |
| IngestDate | Tue Oct 22 15:13:29 EDT 2024 Tue Sep 17 21:29:40 EDT 2024 Fri Oct 25 02:36:37 EDT 2024 Fri Nov 08 20:52:55 EST 2024 Wed Oct 09 16:51:51 EDT 2024 Sat Nov 02 12:18:38 EDT 2024 Tue Jul 16 20:51:34 EDT 2024 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Keywords | clinical trials glomerulonephritis patient engagement knowledge translation |
| Language | English |
| License | This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage). The Author(s) 2023. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c442t-93acd3ffa1fc2002c1736028b5fc6dc225b57cd4e800ced8a51d1df4f57000ff3 |
| Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-3 content type line 23 ObjectType-Review-1 These authors contributed equally as first author. |
| ORCID | 0000-0001-8653-6778 0000-0003-0225-8307 |
| OpenAccessLink | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10457520/ |
| PMID | 37637870 |
| PQID | 2920192196 |
| PQPubID | 2040156 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_08ab217732274b46a552171c82093f2f pubmedcentral_primary_oai_pubmedcentral_nih_gov_10457520 proquest_miscellaneous_2858408495 proquest_journals_2920192196 crossref_primary_10_1177_20543581231191839 pubmed_primary_37637870 sage_journals_10_1177_20543581231191839 |
| PublicationCentury | 2000 |
| PublicationDate | 2023-01-01 |
| PublicationDateYYYYMMDD | 2023-01-01 |
| PublicationDate_xml | – month: 01 year: 2023 text: 2023-01-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | Los Angeles, CA |
| PublicationPlace_xml | – name: Los Angeles, CA – name: England – name: London – name: Sage CA: Los Angeles, CA |
| PublicationTitle | Canadian Journal of Kidney Health and Disease |
| PublicationTitleAlternate | Can J Kidney Health Dis |
| PublicationYear | 2023 |
| Publisher | SAGE Publications Sage Publications Ltd SAGE Publishing |
| Publisher_xml | – name: SAGE Publications – name: Sage Publications Ltd – name: SAGE Publishing |
| References | Navarra, Guzmán, Gallacher 2011; 377 Sethi, Madden, Debiec 2021; 32 Heymann, Hackel, Harwood, Wilson, Hunter 1959; 100 Rauen, Eitner, Fitzner 2015; 373 Hou, Xie, Wang 2023; 6 Tortajada, Gutierrez, Pickering, Praga Terente, Medjeral-Thomas 2019; 114 Parikh, Almaani, Brodsky, Rovin 2020; 76 Barbour, Beaulieu, Gill, Espino-Hernandez, Reich, Levin 2014; 7 Black 2013; 346 Jayne, Rovin, Mysler 2022; 81 Rovin, Adler, Barratt 2021; 100 Cunningham, Benediktsson, Muruve, Hildebrand, Ravani 2018; 5 Ravani, Bertelli, Gill, Ghiggeri 2017; 32 Gadegbeku, Gipson, Holzman 2013; 83 Mejia-Vilet, Malvar, Arazi, Rovin 2022; 101 Pattrapornpisut, Avila-Casado, Reich 2021; 78 Jennette 1988; 12 Zhai, Zhu, Shi, Liu, Lv, Zhang 2016; 95 Gerogianni, Babatsikou, Polikandrioti, Grapsa 2019; 51 Asif, Bargman, Auguste 2022; 31 Furie, Rovin, Houssiau 2020; 383 Barra, Borchin, Burroughs 2018; 36 McGrogan, Franssen, de Vries 2011; 26 Cheung, Rajasekaran, Barratt, Rizk 2021; 10 Coppo 2023; 103 Floege, Amann 2016; 387 Basch, Barbera, Kerrigan, Velikova 2018; 38 Beck, Bonegio, Lambeau 2009; 361 Lv, Wong, Hladunewich 2022; 327 Barbour, Beaulieu, Gill, Djurdjev, Reich, Levin 2013; 14 Poggio, McClelland, Blank 2020; 15 Lin, Liu, Hsu, Tsai 2017; 74 Watts, Keller, Lerner 2022; 33 Levey, Gansevoort, Coresh 2020; 75 Thompson, Cattran, Blank, Nachman 2015; 26 Beck, Salant 2014; 124 Leaf, Appel, Radhakrishnan 2010; 78 Gleeson, Lightstone 2022; 101 Kohan, Barton 2014; 86 Majumdar, McAlister, Furberg 2004; 43 Barbour, Lo, Espino-Hernandez, Gill, Levin 2018; 5 Ju, Chow, Ralph 2019; 19 Hildebrand, Barua, Barbour 2022; 9 Bobart, Han, Tehranian 2021; 16 Johnson, Al Sayah, Buzinski 2020; 20 Furie, Aroca, Cascino 2022; 81 Jayne, Merkel, Schall, Bekker 2021; 384 Sethi, Debiec, Madden 2020; 98 Davison, Klarenbach, Manns 2021; 5 Clyne, Anding-Rost 2021; 14 Eddy, Symons 2003; 362 Lafayette, Rovin, Reich, Tumlin, Floege, Barratt 2020; 5 Sethi, Debiec, Madden 2020; 97 Schick-Makaroff, Tate, Molzahn 2019; 6 Xin, Shi, Xu, Su, Yan, Li 2013; 26 Saxena, Ginzler, Gibson 2023 Thompson, Carroll, Inker 2019; 14 2021; 100 Cheetham, Wilkie, Loud 2022; 42 Canetta, Troost, Mahoney 2019; 95 Elliott, Allu, Beaucage 2021; 8 Barratt, Lafayette, Kristensen 2023; 103 Tomas, Beck, Meyer-Schwesinger 2014; 371 Sallustio, Curci, Chaoul 2021; 36 Carter, Logeman, Howell 2021; 100 Saxena, Teng, Collins, England, Leher 2022; 81 Lv, Zhang, Wong 2017; 318 Suzuki, Kiryluk, Novak 2011; 22 Selvaskandan, Gonzalez-Martin, Barratt, Cheung 2022; 31 Tangri, Garg, Ferguson 2021; 32 Murphy, Mahan, Troost 2020; 5 Pang, D’Antonio, Heale 2019; 6 Walsh, Merkel, Peh 2020; 382 Rovin, Teng, Ginzler 2021; 397 Sethi, Madden, Debiec 2019; 30 Mackensen, Müller, Mougiakakos 2022; 28 Furie, Petri, Zamani 2011; 63 Guerraoui, Prezelin-Reydit, Kolko 2021; 22 Carter, Gutman, Logeman 2020; 15 Dobrozsi, Panepinto 2015; 2015 Ghaddar, Barratt, Barbour 2023; 32 bibr50-20543581231191839 bibr76-20543581231191839 bibr15-20543581231191839 bibr5-20543581231191839 bibr83-20543581231191839 bibr43-20543581231191839 bibr70-20543581231191839 bibr63-20543581231191839 bibr69-20543581231191839 bibr56-20543581231191839 bibr91-20543581231191839 bibr89-20543581231191839 bibr71-20543581231191839 bibr49-20543581231191839 bibr84-20543581231191839 bibr23-20543581231191839 bibr29-20543581231191839 bibr90-20543581231191839 bibr16-20543581231191839 bibr36-20543581231191839 bibr6-20543581231191839 bibr30-20543581231191839 bibr10-20543581231191839 bibr21-20543581231191839 bibr11-20543581231191839 bibr57-20543581231191839 bibr47-20543581231191839 bibr67-20543581231191839 bibr9-20543581231191839 bibr77-20543581231191839 bibr17-20543581231191839 bibr27-20543581231191839 bibr31-20543581231191839 bibr37-20543581231191839 bibr61-20543581231191839 bibr51-20543581231191839 bibr41-20543581231191839 bibr42-20543581231191839 bibr78-20543581231191839 bibr52-20543581231191839 bibr22-20543581231191839 bibr32-20543581231191839 bibr12-20543581231191839 bibr48-20543581231191839 bibr72-20543581231191839 bibr62-20543581231191839 bibr8-20543581231191839 bibr82-20543581231191839 bibr88-20543581231191839 bibr28-20543581231191839 bibr38-20543581231191839 bibr68-20543581231191839 bibr92-20543581231191839 bibr58-20543581231191839 bibr18-20543581231191839 bibr40-20543581231191839 bibr86-20543581231191839 bibr53-20543581231191839 Barra L (bibr60-20543581231191839) 2018; 36 bibr66-20543581231191839 bibr73-20543581231191839 bibr2-20543581231191839 Canadian Institute for Health Information (bibr1-20543581231191839) 2021 bibr93-20543581231191839 bibr79-20543581231191839 bibr59-20543581231191839 bibr7-20543581231191839 bibr26-20543581231191839 bibr39-20543581231191839 bibr81-20543581231191839 bibr13-20543581231191839 bibr46-20543581231191839 bibr87-20543581231191839 bibr19-20543581231191839 bibr80-20543581231191839 bibr20-20543581231191839 bibr33-20543581231191839 bibr3-20543581231191839 bibr34-20543581231191839 bibr54-20543581231191839 bibr64-20543581231191839 bibr74-20543581231191839 bibr4-20543581231191839 bibr44-20543581231191839 bibr14-20543581231191839 bibr24-20543581231191839 bibr55-20543581231191839 bibr85-20543581231191839 bibr25-20543581231191839 bibr35-20543581231191839 bibr45-20543581231191839 bibr65-20543581231191839 bibr75-20543581231191839 |
| References_xml | – volume: 6 start-page: 2054358119877405 year: 2019 article-title: Provincial needs assessment to determine the current state of glomerulonephritis care in Ontario publication-title: Can J Kidney Health Dis contributor: fullname: Heale – volume: 124 start-page: 2307 issue: 6 year: 2014 end-page: 2314 article-title: Membranous nephropathy: from models to man publication-title: J Clin Invest contributor: fullname: Salant – volume: 30 start-page: 1123 issue: 6 year: 2019 end-page: 1136 article-title: Exostosin 1/exostosin 2-associated membranous nephropathy publication-title: J Am Soc Nephrol contributor: fullname: Debiec – volume: 81 start-page: 496 issue: 4 year: 2022 end-page: 506 article-title: Phase II randomised trial of type I interferon inhibitor anifrolumab in patients with active lupus nephritis publication-title: Ann Rheum Dis contributor: fullname: Mysler – volume: 97 start-page: 163 issue: 1 year: 2020 end-page: 174 article-title: Neural epidermal growth factor-like 1 protein (NELL-1) associated membranous nephropathy publication-title: Kidney Int contributor: fullname: Madden – volume: 5 start-page: 2032 issue: 11 year: 2020 end-page: 2041 article-title: Safety, tolerability and efficacy of narsoplimab, a novel MASP-2 inhibitor for the treatment of IgA nephropathy publication-title: Kidney Int Rep contributor: fullname: Barratt – volume: 95 start-page: 1209 issue: 5 year: 2019 end-page: 1224 article-title: Health-related quality of life in glomerular disease publication-title: Kidney Int contributor: fullname: Mahoney – volume: 15 start-page: 1595 issue: 11 year: 2020 end-page: 1602 article-title: Systematic review and meta-analysis of native kidney biopsy complications publication-title: Clin J Am Soc Nephrol contributor: fullname: Blank – volume: 42 start-page: 562 issue: 6 year: 2022 end-page: 570 article-title: Establishing a core outcome measure for life participation in patients receiving peritoneal dialysis: a Standardised Outcomes in Nephrology-Peritoneal Dialysis consensus workshop report publication-title: Perit Dial Int contributor: fullname: Loud – volume: 16 start-page: 1833 issue: 12 year: 2021 end-page: 1839 article-title: Noninvasive diagnosis of PLA2R-associated membranous nephropathy: a validation study publication-title: Clin J Am Soc Nephrol contributor: fullname: Tehranian – volume: 31 start-page: 1321 issue: 12 year: 2022 end-page: 1338 article-title: IgA nephropathy: an overview of drug treatments in clinical trials publication-title: Expert Opin Investig Drugs contributor: fullname: Cheung – volume: 397 start-page: 2070 issue: 10289 year: 2021 end-page: 2080 article-title: Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial publication-title: Lancet contributor: fullname: Ginzler – volume: 26 start-page: 414 issue: 2 year: 2011 end-page: 430 article-title: The incidence of primary glomerulonephritis worldwide: a systematic review of the literature publication-title: Nephrol Dial Transplant contributor: fullname: de Vries – volume: 32 start-page: 1249 issue: 5 year: 2021 end-page: 1261 article-title: Protocadherin 7-associated membranous nephropathy publication-title: J Am Soc Nephrol contributor: fullname: Debiec – volume: 101 start-page: 224 issue: 2 year: 2022 end-page: 226 article-title: BLISS-LN trial revisited: function matters publication-title: Kidney Int contributor: fullname: Lightstone – volume: 384 start-page: 599 issue: 7 year: 2021 end-page: 609 article-title: Avacopan for the treatment of ANCA-associated vasculitis publication-title: N Engl J Med contributor: fullname: Bekker – volume: 7 start-page: 538 issue: 6 year: 2014 end-page: 545 article-title: The need for improved uptake of the KDIGO glomerulonephritis guidelines into clinical practice in Canada: a survey of nephrologists publication-title: Clin Kidney J contributor: fullname: Levin – volume: 78 start-page: 337 issue: 4 year: 2010 end-page: 342 article-title: Glomerular disease: why is there a dearth of high quality clinical trials publication-title: Kidney Int contributor: fullname: Radhakrishnan – volume: 318 start-page: 432 issue: 5 year: 2017 end-page: 442 article-title: Effect of oral methylprednisolone on clinical outcomes in patients with IgA nephropathy: the TESTING randomized clinical trial publication-title: JAMA contributor: fullname: Wong – volume: 100 year: 2021 article-title: KDIGO 2021 clinical practice guideline for the management of glomerular diseases publication-title: Kidney Int – volume: 86 start-page: 896 issue: 5 year: 2014 end-page: 904 article-title: Endothelin and endothelin antagonists in chronic kidney disease publication-title: Kidney Int contributor: fullname: Barton – volume: 101 start-page: 242 issue: 2 year: 2022 end-page: 255 article-title: The lupus nephritis management renaissance publication-title: Kidney Int contributor: fullname: Rovin – volume: 51 start-page: 113 issue: 1 year: 2019 end-page: 118 article-title: Management of anxiety and depression in haemodialysis patients: the role of non-pharmacological methods publication-title: Int Urol Nephrol contributor: fullname: Grapsa – volume: 361 start-page: 11 issue: 1 year: 2009 end-page: 21 article-title: M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy publication-title: N Engl J Med contributor: fullname: Lambeau – volume: 6 issue: 2 year: 2023 article-title: Effectiveness of mycophenolate mofetil among patients with progressive IgA nephropathy publication-title: JAMA Netw Open contributor: fullname: Wang – volume: 78 start-page: 429 issue: 3 year: 2021 end-page: 441 article-title: IgA nephropathy: core curriculum 2021 publication-title: Am J Kidney Dis contributor: fullname: Reich – volume: 10 start-page: 2493 issue: 11 year: 2021 article-title: An update on the current state of management and clinical trials for IgA nephropathy publication-title: J Clin Med contributor: fullname: Rizk – year: 2023 article-title: Safety and efficacy of long-term voclosporin treatment for lupus nephritis in the Phase 3 AURORA 2 clinical trial publication-title: Arthritis Rheumatol contributor: fullname: Gibson – volume: 83 start-page: 749 issue: 4 year: 2013 end-page: 756 article-title: Design of the nephrotic syndrome study network (NEPTUNE) to evaluate primary glomerular nephropathy by a multidisciplinary approach publication-title: Kidney Int contributor: fullname: Holzman – volume: 32 start-page: 1791 issue: 7 year: 2021 end-page: 1800 article-title: Effects of a knowledge-translation intervention on early dialysis initiation: a cluster randomized trial publication-title: J Am Soc Nephrol contributor: fullname: Ferguson – volume: 100 start-page: 660 issue: 4 year: 1959 end-page: 664 article-title: Production of nephrotic syndrome in rats by Freund’s adjuvants and rat kidney suspensions publication-title: Proc Soc Exp Biol Med contributor: fullname: Hunter – volume: 382 start-page: 622 issue: 7 year: 2020 end-page: 631 article-title: Plasma exchange and glucocorticoids in severe ANCA-associated vasculitis publication-title: N Engl J Med contributor: fullname: Peh – volume: 14 start-page: 469 issue: 3 year: 2019 end-page: 481 article-title: Proteinuria reduction as a surrogate end point in trials of IgA nephropathy publication-title: Clin J Am Soc Nephrol contributor: fullname: Inker – volume: 31 start-page: 278 issue: 3 year: 2022 end-page: 282 article-title: A review of the AURORA and BLISS trials: will it revolutionize the treatment of lupus nephritis? publication-title: Curr Opin Nephrol Hypertens contributor: fullname: Auguste – volume: 22 start-page: 1795 issue: 10 year: 2011 end-page: 1803 article-title: The pathophysiology of IgA nephropathy publication-title: J Am Soc Nephrol contributor: fullname: Novak – volume: 327 start-page: 1888 issue: 19 year: 2022 end-page: 1898 article-title: Effect of oral methylprednisolone on decline in kidney function or kidney failure in patients with IgA nephropathy: the TESTING randomized clinical trial publication-title: JAMA contributor: fullname: Hladunewich – volume: 32 start-page: 263 issue: 3 year: 2023 end-page: 270 article-title: An update on corticosteroid treatment for IgA nephropathy publication-title: Curr Opin Nephrol Hypertens contributor: fullname: Barbour – volume: 387 start-page: 2036 issue: 10032 year: 2016 end-page: 2048 article-title: Primary glomerulonephritides publication-title: Lancet contributor: fullname: Amann – volume: 377 start-page: 721 issue: 9767 year: 2011 end-page: 731 article-title: Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial publication-title: Lancet contributor: fullname: Gallacher – volume: 36 start-page: 452 issue: 3 year: 2021 end-page: 464 article-title: High levels of gut-homing immunoglobulin A+ B lymphocytes support the pathogenic role of intestinal mucosal hyperresponsiveness in immunoglobulin A nephropathy patients publication-title: Nephrol Dial Transplant contributor: fullname: Chaoul – volume: 74 start-page: 128 year: 2017 end-page: 137 article-title: Effects of self-management on chronic kidney disease: a meta-analysis publication-title: Int J Nurs Stud contributor: fullname: Tsai – volume: 8 start-page: 20543581211004803 year: 2021 article-title: Defining the scope of knowledge translation within a national, patient-oriented Kidney Research Network publication-title: Can J Kidney Health Dis contributor: fullname: Beaucage – volume: 28 start-page: 2124 issue: 10 year: 2022 end-page: 2132 article-title: Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus publication-title: Nat Med contributor: fullname: Mougiakakos – volume: 38 start-page: 122 year: 2018 end-page: 134 article-title: Implementation of patient-reported outcomes in routine medical care publication-title: Am Soc Clin Oncol Educ Book contributor: fullname: Velikova – volume: 5 start-page: 1679 issue: 10 year: 2020 end-page: 1689 article-title: Longitudinal changes in health-related quality of life in primary glomerular disease: results from the CureGN study publication-title: Kidney Int Rep contributor: fullname: Troost – volume: 32 year: 2017 article-title: Clinical trials in minimal change disease publication-title: Nephrol Dial Transplant contributor: fullname: Ghiggeri – volume: 6 start-page: 2054358119879451 year: 2019 article-title: Use of electronic patient reported outcomes in clinical nephrology practice: a qualitative pilot study publication-title: Can J Kidney Health Dis contributor: fullname: Molzahn – volume: 373 start-page: 2225 issue: 23 year: 2015 end-page: 2236 article-title: Intensive supportive care plus immunosuppression in IgA nephropathy publication-title: N Engl J Med contributor: fullname: Fitzner – volume: 95 issue: 11 year: 2016 article-title: Increased APRIL expression induces IgA1 aberrant glycosylation in IgA nephropathy publication-title: Medicine (Baltimore) contributor: fullname: Zhang – volume: 63 start-page: 3918 issue: 12 year: 2011 end-page: 3930 article-title: A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus publication-title: Arthritis Rheum contributor: fullname: Zamani – volume: 26 start-page: 683 issue: 4 year: 2013 end-page: 690 article-title: Serum BAFF is elevated in patients with IgA nephropathy and associated with clinical and histopathological features publication-title: J Nephrol contributor: fullname: Li – volume: 15 start-page: 673 issue: 5 year: 2020 end-page: 684 article-title: Identifying outcomes important to patients with glomerular disease and their caregivers publication-title: Clin J Am Soc Nephrol contributor: fullname: Logeman – volume: 2015 start-page: 501 year: 2015 end-page: 506 article-title: Patient-reported outcomes in clinical practice publication-title: Hematology Am Soc Hematol Educ Program contributor: fullname: Panepinto – volume: 14 start-page: 236 year: 2013 article-title: An overview of the British Columbia Glomerulonephritis network and registry: integrating knowledge generation and translation within a single framework publication-title: BMC Nephrol contributor: fullname: Levin – volume: 371 start-page: 2277 issue: 24 year: 2014 end-page: 2287 article-title: Thrombospondin type-1 domain-containing 7A in idiopathic membranous nephropathy publication-title: N Engl J Med contributor: fullname: Meyer-Schwesinger – volume: 81 start-page: 325 year: 2022 end-page: 325 article-title: POS0186 voclosporin for lupus nephritis: results of the two-year AURORA 2 continuation study publication-title: Ann Rheum Dis contributor: fullname: Leher – volume: 36 start-page: 58 year: 2018 end-page: 64 article-title: Impact of vasculitis on employment and income publication-title: Clin Exp Rheumatol contributor: fullname: Burroughs – volume: 100 start-page: 881 issue: 4 year: 2021 end-page: 893 article-title: Development of an international Delphi survey to establish core outcome domains for trials in adults with glomerular disease publication-title: Kidney Int contributor: fullname: Howell – volume: 100 start-page: 753 issue: 4 year: 2021 end-page: 779 article-title: Executive summary of the KDIGO 2021 guideline for the management of glomerular diseases publication-title: Kidney Int contributor: fullname: Barratt – volume: 12 start-page: 348 issue: 5 year: 1988 end-page: 352 article-title: The immunohistology of IgA nephropathy publication-title: Am J Kidney Dis contributor: fullname: Jennette – volume: 346 year: 2013 article-title: Patient reported outcome measures could help transform healthcare publication-title: BMJ contributor: fullname: Black – volume: 43 start-page: 1738 issue: 10 year: 2004 end-page: 1742 article-title: From knowledge to practice in chronic cardiovascular disease: a long and winding road publication-title: J Am Coll Cardiol contributor: fullname: Furberg – volume: 362 start-page: 629 issue: 9384 year: 2003 end-page: 639 article-title: Nephrotic syndrome in childhood publication-title: Lancet contributor: fullname: Symons – volume: 383 start-page: 1117 issue: 12 year: 2020 end-page: 1128 article-title: Two-year, randomized, controlled trial of belimumab in lupus nephritis publication-title: N Engl J Med contributor: fullname: Houssiau – volume: 9 start-page: 20543581221089094 year: 2022 article-title: The Canadian Glomerulonephritis Registry (CGNR) and translational research initiative: rationale and clinical research protocol publication-title: Can J Kidney Health Dis contributor: fullname: Barbour – volume: 14 year: 2021 article-title: Exercise training in chronic kidney disease-effects, expectations and adherence publication-title: Clin Kidney J contributor: fullname: Anding-Rost – volume: 5 start-page: 93 year: 2021 article-title: Patient-reported outcome measures in the care of in-centre hemodialysis patients publication-title: J Patient Rep Outcomes contributor: fullname: Manns – volume: 22 start-page: 357 issue: 1 year: 2021 article-title: Patient-reported outcome measures in hemodialysis patients: results of the first multicenter cross-sectional ePROMs study in France publication-title: BMC Nephrol contributor: fullname: Kolko – volume: 76 start-page: 265 issue: 2 year: 2020 end-page: 281 article-title: Update on lupus nephritis: core curriculum 2020 publication-title: Am J Kidney Dis contributor: fullname: Rovin – volume: 5 start-page: 2054358118799690 year: 2018 article-title: Trends in biopsy-based diagnosis of kidney disease: a population study publication-title: Can J Kidney Health Dis contributor: fullname: Ravani – volume: 114 start-page: 123 year: 2019 end-page: 132 article-title: The role of complement in IgA nephropathy publication-title: Mol Immunol contributor: fullname: Medjeral-Thomas – volume: 26 start-page: 2930 issue: 12 year: 2015 end-page: 2937 article-title: Complete and partial remission as surrogate end points in membranous nephropathy publication-title: J Am Soc Nephrol contributor: fullname: Nachman – volume: 75 start-page: 84 issue: 1 year: 2020 end-page: 104 article-title: Change in albuminuria and GFR as end points for clinical trials in early stages of CKD: a scientific workshop sponsored by the National Kidney Foundation in collaboration with the US Food and Drug Administration and European Medicines Agency publication-title: Am J Kidney Dis contributor: fullname: Coresh – volume: 20 start-page: 731 issue: 1 year: 2020 article-title: A cluster randomized controlled trial for the Evaluation of routinely Measured PATient reported outcomes in HemodialYsis care (EMPATHY): a study protocol publication-title: BMC Health Serv Res contributor: fullname: Buzinski – volume: 33 start-page: 238 issue: 1 year: 2022 end-page: 252 article-title: Discovery of autoantibodies targeting nephrin in minimal change disease supports a novel autoimmune etiology publication-title: J Am Soc Nephrol contributor: fullname: Lerner – volume: 81 start-page: 100 issue: 1 year: 2022 end-page: 107 article-title: B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: a randomised, double-blind, placebo-controlled trial publication-title: Ann Rheum Dis contributor: fullname: Cascino – volume: 103 start-page: 258 issue: 2 year: 2023 end-page: 261 article-title: A disease-modifying approach to the treatment of IgA nephropathy targeting mucosal IgA synthesis and beyond publication-title: Kidney Int contributor: fullname: Coppo – volume: 98 start-page: 1253 issue: 5 year: 2020 end-page: 1264 article-title: Semaphorin 3B-associated membranous nephropathy is a distinct type of disease predominantly present in pediatric patients publication-title: Kidney Int contributor: fullname: Madden – volume: 103 start-page: 391 issue: 2 year: 2023 end-page: 402 article-title: Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy publication-title: Kidney Int contributor: fullname: Kristensen – volume: 19 start-page: 2306 issue: 8 year: 2019 end-page: 2317 article-title: Patient-reported outcome measures for life participation in kidney transplantation: a systematic review publication-title: Am J Transplant contributor: fullname: Ralph – volume: 5 start-page: 2054358118759551 year: 2018 article-title: The BC glomerulonephritis network: improving access and reducing the cost of immunosuppressive treatments for glomerular diseases publication-title: Can J Kidney Health Dis contributor: fullname: Levin – ident: bibr31-20543581231191839 doi: 10.1038/ki.2014.143. – ident: bibr43-20543581231191839 doi: 10.1016/j.ekir.2020.08.003. – ident: bibr46-20543581231191839 doi: 10.5301/jn.5000218. – ident: bibr83-20543581231191839 doi: 10.1200/EDBK_200383. – ident: bibr35-20543581231191839 – ident: bibr49-20543581231191839 doi: 10.1056/NEJMoa2001180. – ident: bibr59-20543581231191839 doi: 10.1038/ki.2010.156. – ident: bibr30-20543581231191839 – ident: bibr81-20543581231191839 doi: 10.1016/j.kint.2021.04.027. – ident: bibr17-20543581231191839 doi: 10.1016/S0140-6736(16)00272-5. – ident: bibr20-20543581231191839 doi: 10.1681/ASN.2021060794. – ident: bibr86-20543581231191839 doi: 10.1177/2054358119879451. – ident: bibr58-20543581231191839 doi: 10.1002/art.42657 – ident: bibr21-20543581231191839 doi: 10.1053/j.ajkd.2021.01.024. – ident: bibr52-20543581231191839 doi: 10.1016/S0140-6736(21)00578-X. – ident: bibr10-20543581231191839 doi: 10.2215/CJN.04710420. – ident: bibr28-20543581231191839 doi: 10.1016/j.kint.2022.10.019. – ident: bibr55-20543581231191839 doi: 10.1016/S0140-6736(10)61354-2. – ident: bibr29-20543581231191839 doi: 10.1080/13543784.2022.2160315. – ident: bibr65-20543581231191839 doi: 10.1001/jama.2022.5368. – ident: bibr78-20543581231191839 – ident: bibr87-20543581231191839 doi: 10.1186/s12882-021-02551-3. – ident: bibr23-20543581231191839 doi: 10.1016/j.kint.2021.05.015. – ident: bibr25-20543581231191839 doi: 10.1056/NEJMoa1415463. – ident: bibr48-20543581231191839 doi: 10.1016/j.kint.2021.09.012. – ident: bibr79-20543581231191839 doi: 10.1182/asheducation-2015.1.501. – ident: bibr77-20543581231191839 doi: 10.1681/ASN.2020091254. – ident: bibr7-20543581231191839 doi: 10.3181/00379727-100-24736. – ident: bibr40-20543581231191839 doi: 10.3390/jcm10112493. – ident: bibr50-20543581231191839 doi: 10.1136/annrheumdis-2021-220920. – ident: bibr72-20543581231191839 doi: 10.1681/ASN.2015010091. – ident: bibr13-20543581231191839 doi: 10.1681/ASN.2018080852. – ident: bibr36-20543581231191839 – ident: bibr66-20543581231191839 doi: 10.1001/jamanetworkopen.2022.54054. – ident: bibr47-20543581231191839 doi: 10.1053/j.ajkd.2019.10.017. – ident: bibr6-20543581231191839 doi: 10.1172/JCI72270. – ident: bibr88-20543581231191839 doi: 10.1186/s12913-020-05557-z. – ident: bibr32-20543581231191839 – ident: bibr51-20543581231191839 doi: 10.1136/annrheumdis-2021-221478. – ident: bibr91-20543581231191839 doi: 10.1093/ckj/sfab012. – ident: bibr39-20543581231191839 – ident: bibr76-20543581231191839 doi: 10.1016/j.jacc.2003.12.043. – ident: bibr61-20543581231191839 doi: 10.1038/ki.2012.428. – ident: bibr92-20543581231191839 doi: 10.1007/s11255-018-2022-7. – ident: bibr15-20543581231191839 doi: 10.1016/j.kint.2020.05.030. – ident: bibr2-20543581231191839 doi: 10.1093/ndt/gfq665. – ident: bibr22-20543581231191839 doi: 10.1681/ASN.2011050464. – ident: bibr63-20543581231191839 doi: 10.1186/1471-2369-14-236. – ident: bibr9-20543581231191839 doi: 10.1177/2054358118799690. – ident: bibr93-20543581231191839 doi: 10.1016/j.ijnurstu.2017.06.008. – ident: bibr44-20543581231191839 doi: 10.1097/MD.0000000000003099. – ident: bibr27-20543581231191839 doi: 10.1016/j.kint.2022.09.017. – ident: bibr3-20543581231191839 doi: 10.1016/j.kint.2021.05.021. – ident: bibr4-20543581231191839 doi: 10.1177/20543581211004803. – ident: bibr37-20543581231191839 – ident: bibr68-20543581231191839 doi: 10.1056/NEJMoa2023386. – ident: bibr42-20543581231191839 doi: 10.1016/j.molimm.2019.07.017. – ident: bibr33-20543581231191839 – ident: bibr57-20543581231191839 doi: 10.1136/annrheumdis-2022-eular.4162. – ident: bibr8-20543581231191839 doi: 10.1056/NEJMoa0810457. – ident: bibr38-20543581231191839 – ident: bibr14-20543581231191839 doi: 10.1016/j.kint.2019.09.014. – ident: bibr89-20543581231191839 doi: 10.1186/s41687-021-00365-3. – volume-title: Treatment of End-Stage Organ Failure in Canada, Canadian Organ Replacement Register, 2011 to 2020: End-Stage Kidney Disease and Kidney Transplants — Data Tables year: 2021 ident: bibr1-20543581231191839 contributor: fullname: Canadian Institute for Health Information – ident: bibr18-20543581231191839 doi: 10.1016/S0140-6736(03)14184-0. – ident: bibr90-20543581231191839 doi: 10.1016/j.kint.2018.12.018. – ident: bibr82-20543581231191839 doi: 10.1111/ajt.15267. – ident: bibr53-20543581231191839 doi: 10.1038/s41591-022-02017-5. – volume: 36 start-page: 58 year: 2018 ident: bibr60-20543581231191839 publication-title: Clin Exp Rheumatol contributor: fullname: Barra L – ident: bibr73-20543581231191839 doi: 10.1177/2054358118759551. – ident: bibr5-20543581231191839 doi: 10.1177/2054358119877405. – ident: bibr12-20543581231191839 doi: 10.1056/NEJMoa1409354. – ident: bibr71-20543581231191839 doi: 10.2215/CJN.08600718. – ident: bibr24-20543581231191839 doi: 10.1097/MNH.0000000000000881. – ident: bibr74-20543581231191839 doi: 10.1097/MNH.0000000000000792. – ident: bibr19-20543581231191839 doi: 10.1093/ndt/gfw235. – ident: bibr26-20543581231191839 doi: 10.1001/jama.2017.9362. – ident: bibr54-20543581231191839 doi: 10.1002/art.30613. – ident: bibr69-20543581231191839 – ident: bibr62-20543581231191839 doi: 10.1177/20543581221089094. – ident: bibr67-20543581231191839 doi: 10.1056/NEJMoa1803537. – ident: bibr75-20543581231191839 doi: 10.1093/ckj/sfu104. – ident: bibr85-20543581231191839 doi: 10.1016/j.ekir.2020.06.041. – ident: bibr56-20543581231191839 doi: 10.1016/j.kint.2021.12.003. – ident: bibr64-20543581231191839 doi: 10.2215/CJN.13101019. – ident: bibr34-20543581231191839 – ident: bibr80-20543581231191839 doi: 10.1136/bmj.f167. – ident: bibr45-20543581231191839 doi: 10.1093/ndt/gfaa264. – ident: bibr70-20543581231191839 doi: 10.1053/j.ajkd.2019.06.009. – ident: bibr11-20543581231191839 doi: 10.2215/CJN.05480421. – ident: bibr16-20543581231191839 doi: 10.1681/ASN.2020081165. – ident: bibr84-20543581231191839 doi: 10.1177/08968608221096560. – ident: bibr41-20543581231191839 doi: 10.1016/s0272-6386(88)80022-2. |
| SSID | ssj0001255791 |
| Score | 2.2680097 |
| SecondaryResourceType | review_article |
| Snippet | Purpose of review:
Glomerulonephritis refers to a rare group of diseases characterized by glomerular inflammation, which collectively are a common cause of... Glomerulonephritis refers to a rare group of diseases characterized by glomerular inflammation, which collectively are a common cause of kidney failure. Until... Purpose of review: Glomerulonephritis refers to a rare group of diseases characterized by glomerular inflammation, which collectively are a common cause of... Purpose of reviewGlomerulonephritis refers to a rare group of diseases characterized by glomerular inflammation, which collectively are a common cause of... |
| SourceID | doaj pubmedcentral proquest crossref pubmed sage |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Publisher |
| StartPage | 20543581231191839 |
| SubjectTerms | Clinical trials Medical research Narrative Review |
| SummonAdditionalLinks | – databaseName: Directory of Open Access Journals dbid: DOA link: http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3dS-QwEB9OHw5fRL2vnh9EEASh2KZJk_qmd67CoS-ecG-l-UJF22N3-_8703bXXVTu5d5Kk7bDZJL5TTL9DcCBk0pZmSUxBUCx8HS-W1U2ds7YxHhtCkf_O1_eqOs_-uc50eTMS31RTlhPD9wr7jjRlUHYrNDwlDAiryQ6HJVa9FxFFnjoVt9ELwRT_e6KlKpIh2NMYljiiE2I6wvxDIYomoqDLziijq__LZD5OldyIeGr80GjDVgfwCM77YXehA--3oKPV8Px-Cd4-DXbIWOdD-rz3Nh9zS4emyc_bh-b2uPoEY_RCbtpu2KJfkIdFvrjF2b5eGw0bp4YYkR2htZ8x6YNXjiq8PkZbkfnv39cxkMxhdgKwadxkVXWZSFUabCUmGFTleUILowMNncWp7WRyjrhEUFa73QlU5e6IAIR4CchZF9gtUYhvwEzBbe5UTa13AmVBVKqKITh-HIhBY_gaKbZ8m_PmVGmA634q2GI4Ix0P-9IdNfdDTSCcjCC8l9GEMHObOTKYQ5OSqrDRWxvRR7B_rwZZw8diVS1b1rsoxGAJRqjxAi-9gM9l4SWXlrOItBLJrAk6nJLfX_XMXRjjIswmOOjh2QtLzK9q4bv_0MN27DGEYP1O0Q7sDodt34XViau3eumxzOKsg5x priority: 102 providerName: Directory of Open Access Journals |
| Title | Knowledge Translation in Glomerulonephritis: Successes in Translational Research From the Bench to Bedside |
| URI | https://journals.sagepub.com/doi/full/10.1177/20543581231191839 https://www.ncbi.nlm.nih.gov/pubmed/37637870 https://www.proquest.com/docview/2920192196 https://search.proquest.com/docview/2858408495 https://pubmed.ncbi.nlm.nih.gov/PMC10457520 https://doaj.org/article/08ab217732274b46a552171c82093f2f |
| Volume | 10 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3db9MwED_RPSBeEN-EjclISEhIWRPHjhPe2FiZhIaQBhJvUfzFitpkapv_f3dOUloNXniLEis-3Z3t39nn3wG8tVIpI7MkpgAoFo7Od-vaxNZqk2hX6NLSfeeLK_X1Z_HpnGhy8vEuTEjaN3p-0iyWJ838OuRW3izNdMwTm367PMMQAlEGT6YTmCA43InR-50VKVWZDkeYxK7EEZcQzxdiGQxPCioMvrMIBa7-vwHMu3mSO8leYf2ZPYKHA3BkH3sBH8M91zyB-5fD0fhT-P1l3B1jYf3pc9zYvGGfF-3SrbpF2zi0HHEYfWBXXSiU6NbUYKc99jDm4rHZql0yxIfsFD35mm1afLBU3fMZ_Jidfz-7iIdCCrERgm_iMquNzbyvU28oKcOkKssRWGjpTW4NDmktlbHCIXo0zha1TG1qvfBEfp94nz2HgwaFfAlMl9zkWpnUcCtU5kmpohSa48-FFDyC96Nmq5ueL6NKB0rxO2aI4JR0v21IVNfhRbv6VQ0Gr5Ki1hg3KZx5lNAiryUiDpUahC5l5rmP4Gi0XDWMv3VFNbiI6a3MI3iz_Ywjh45D6sa1HbYpEHwlBUaIEbzoDb2VhKZdmsoiKPZcYE_U_S_orIGde3TOCN6Rt_yR6Z9qePX_nRzCA46oq98TOoKDzapzr2Gytt1x2F04DkPjFhbzEF4 |
| link.rule.ids | 230,314,315,729,782,786,794,866,887,2108,27933,27935,27936,53803,53805 |
| linkProvider | National Library of Medicine |
| linkToHtml | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3db9MwED-xIQEvfA1YYAwjIU1CypoPJ054Y2Nd0dYJaUPiLYq_WKc2mdrm_-fOSUqrwcveothKTr47-3f2-XcAn3QihEriwKcAyOeGznfLUvlaSxVIk8lc033n0aW4-JV9OyGanLS_C-OS9pWcHFbT2WE1uXa5lbczNejzxAY_xscYQiDKiILBFjxEhw3itSi93VtJEpGH3SEm8StFiEyI6QvRDAYoGZUGX1uGHFv_vyDm3UzJtXQvtwINn91X9ufwtMOc7Gvb_gIemOolPBp3p-o7cHPWb6wxt3S16XFsUrHTaT0z82ZaVwaVTvRHX9hl42osmgV1WOuPf-jT-NhwXs8YQkt2hE5wzZY1PmgqDPoKfg5Pro5HfleDwVecR0s_j0ulY2vL0CrK51ChiFPEJDKxKtUKZwOZCKW5QeCpjM7KJNShttwSb35gbfwatisUcheYzCOVSqFCFWkuYkva4DmXEX6cJzzy4HOvkuK2pdoowo6N_I7-PDgipa06Eku2e1HPfxfdeBdBVkoMuQROWoJLnpYJghURKkQ9eWwj68Fer_Kic91FQeW7iCQuTz34uGpGp6OTlLIydYN9MsRtQYbBpQdvWgtZSUIzNs2CHmQbtrMh6mYL2ooj9u5tw4MDMrO_Mv13GN7e_ycf4PHoanxenH-_OHsHTyIEb-3W0h5sL-eNeQ9bC93sO8_6A_iKJR0 |
| linkToPdf | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Za9tAEB6aFEJfmp6J0qTdQqFQUKxjVyvlrTnclDQhkBb6JrRX4mJLxrb-f2d0ODZpX9o3IQ3SsDOz-83u6BuAD0ZIqUUc-JQA-dzS-W5RaN8YpQNlU5UZ-t_5_EZe_UxPz4gm56j_F6Yp2tdqdFiOJ4fl6K6prZxO9KCvExtcX55gCoEoIwoGU-MGG_AYgzYQK5l6u78ihMzC7iCTOJYiRCfE9oWIBpOUlNqDryxFDWP_n2Dmw2rJlZKvZhUabv-P_s_gaYc92edW5jk8suUL2LrsTtdfwq-LfoONNUtYWybHRiX7Mq4mdlaPq9Ki8YkG6Yjd1E2vRTsngRV5_EJfzseGs2rCEGKyYwyGO7ao8MJQg9BX8GN49v3k3O96Mfia82jhZ3GhTexcETpNdR06lHGC2EQJpxOjcVZQQmrDLQJQbU1aiNCExnFH_PmBc_Fr2CxRyV1gKot0oqQOdWS4jB1ZhGdcRfhyLnjkwafeLPm0pdzIw46V_IENPTgmwy0FiS27uVHNbvNuzPMgLRSmXhInL8kVTwqBoEWGGtFPFrvIebDfmz3vQnieUxsvIovLEg_eLx9j8NGJSlHaqkaZFPFbkGKS6cFO6yVLTWjmptnQg3TNf9ZUXX-C_tIQfPf-4cFHcrV7nf46DHv__pF3sHV9Osy_fb26eANPIsRw7Q7TPmwuZrU9gI25qd82wfUbRxwnnQ |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Knowledge+Translation+in+Glomerulonephritis%3A+Successes+in+Translational+Research+From+the+Bench+to+Bedside&rft.jtitle=Canadian+Journal+of+Kidney+Health+and+Disease&rft.au=Yau%2C+Kevin&rft.au=Wang%2C+Carol&rft.au=Al+Batran%2C+Rami&rft.au=Macphee%2C+Anne&rft.date=2023-01-01&rft.pub=SAGE+Publications&rft.issn=2054-3581&rft.eissn=2054-3581&rft.volume=10&rft_id=info:doi/10.1177%2F20543581231191839&rft.externalDocID=10.1177_20543581231191839 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2054-3581&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2054-3581&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2054-3581&client=summon |